Theratechnologies (TSE:TH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theratechnologies Inc. has secured exclusive rights from Ionis Pharmaceuticals to commercialize two RNA-targeted investigational medicines, olezarsen and donidalorsen, in Canada. This agreement aims to expand Theratechnologies’ portfolio beyond HIV treatments by addressing unmet medical needs for conditions like familial chylomicronemia syndrome and hereditary angioedema. Both companies are committed to delivering innovative therapies in North America, with regulatory submissions to Health Canada expected in 2025.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
